Brown Advisory’s Quest Diagnostics DGX Stock Holding History

Brown Advisory’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-5,000	Closed	-$268K	–	989
2013 Q4	$268K	Buy	+5,000	New	+$297K	﹤0.01%	775

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Brown Advisory's DGX Position: Q1 2026 in Review

Brown Advisory reduced its Quest Diagnostics (DGX) stake by 1.4% in Q1 2026, selling an estimated $19.8K and leaving 7,185 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Brown Advisory first reported a position in DGX in Q4 2013 and has held it in 42 quarters since. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Brown Advisory held 7,185 shares of Quest Diagnostics worth $1.41M as of Q1 2026.
Brown Advisory sold 102 Quest Diagnostics shares in Q1 2026, an estimated $19.8K.
Quest Diagnostics made up ﹤0.01% of Brown Advisory's portfolio in Q1 2026, its #759 holding.
Brown Advisory first reported a position in Quest Diagnostics in Q4 2013 and has held it in 42 quarters since.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.